Schulz K D
Fortschr Med. 1980 Sep 25;98(36):1359-64.
During the last decade many new experimental and clinical data were published demonstrating the inclusion of estrogens, progestagens, androgens, corticosteroids, prolactin, growth hormone and of insulin in the endocrine control of normal mammary tissue. Different hormonal disorders, such as lowered progesterone-estrogen-index (P.E.I.), anovulation, hyperprolactinemia, or increased prolactin-sensitivity of mammary tissue, are often responsible for the induction and/or maintenance of benign breast disease. therefore the endocrine treatment possesses deciding importance for the improvement or removal of breast symptoms. The present paper evaluates the role of progestagens, prolactin-inhibitors or anti-gonadotropins in the differentiated therapy of mastodynia, mastopathia, mammary secretion, mastitis, mammary hyperplasia, premenstrual syndrome and other disturbances. Dose levels and side effects of the various drugs are reviewed. The relation to other therapeutic procedures, as non-hormonal preparations or operative methods, is discussed.
在过去十年间，发表了许多新的实验和临床数据，表明雌激素、孕激素、雄激素、皮质类固醇、催乳素、生长激素以及胰岛素参与了正常乳腺组织的内分泌调控。不同的激素紊乱，如孕酮 - 雌激素指数（P.E.I.）降低、无排卵、高催乳素血症或乳腺组织对催乳素敏感性增加，常常是导致良性乳腺疾病发生和/或维持的原因。因此，内分泌治疗对于改善或消除乳腺症状具有决定性意义。本文评估了孕激素、催乳素抑制剂或抗促性腺激素在乳腺疼痛、乳腺病、乳腺分泌、乳腺炎、乳腺增生、经前综合征及其他病症的个体化治疗中的作用。综述了各种药物的剂量水平和副作用。讨论了其与其他治疗方法（如非激素制剂或手术方法）的关系。
